BioPorto's Annual General Meeting

BioPorto A/S held its Annual General Meeting today where the shareholders approved the report on the Company's activities and adopted the 2016 Annual Report. In addition, the Annual General Meeting adopted the proposed profit/loss allocation and discharge was given to the Board of Directors and the Management Board. Finally, the remuneration of the Board of Directors was approved.

Proposals from the Board of Directors in Item 6 of the agenda were adopted as follows:

• Proposal for the annual report and interim reports to be prepared and presented in English. 
• Proposal for company announcements to be prepared and published in English.
• Proposal for approval of Remuneration Policy and Guidelines for Incentive-based remuneration.
• Proposal for renewal of the authorization to issue convertible bonds.

Thomas Magnussen, Torben A. Nielsen and Niels Christian Nielsen offered themselves for re-election and were re-elected. In addition, Kirsten Drejer was elected as a new board member. Immediately after the Annual General Meeting, the Board of Directors elected Thomas Magnussen as its chairman and Torben A. Nielsen as its vice chairman.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor.

Hellerup, April 21, 2017

BioPorto A/S

The Board of Directors

For further information, please contact:

Peter Morch Eriksen, CEO

Gry Husby Larsen, General Counsel

Telephone +45 45 29 00 00, e-mail investor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.

Vedhæftede filer:

08 announcement 2017 04 21.pdf